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Abstract. As therapeutic trials target early stages of Parkinson’s disease (PD), appropriate patient selection based purely on
clinical criteria poses significant challenges. Members of the Critical Path for Parkinson’s Consortium formally submitted
documentation to the European Medicines Agency (EMA) supporting the use of Dopamine Transporter (DAT) neuroimaging
in early PD. Regulatory documents included a comprehensive literature review, a proposed analysis plan of both observational
and clinical trial data, and an assessment of biomarker reproducibility and reliability. The research plan included longitudinal
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analysis of the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) and the Parkinson’s Progression Markers
Initiative (PPMI) study to estimate the degree of enrichment achieved and impact on future trials in subjects with early motor
PD. The presence of reduced striatal DAT binding based on visual reads of single photon emission tomography (SPECT)
scans in early motor PD subjects was an independent predictor of faster decline in UPDRS Parts II and III as compared
to subjects with scans without evidence of dopaminergic deficit (SWEDD) over 24 months. The EMA issued in 2018 a
full Qualification Opinion for the use of DAT as an enrichment biomarker in PD trials targeting subjects with early motor
symptoms. Exclusion of SWEDD subjects in future clinical trials targeting early motor PD subjects aims to enrich clinical
trial populations with idiopathic PD patients, improve statistical power, and exclude subjects who are unlikely to progress
clinically from being exposed to novel test therapeutics.
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BACKGROUND
Parkinson’s disease (PD) is the second most com-
mon neurodegenerative disease affecting 2% to 3%
of people over 65 years of age [1] and has been
recently reported to be the most rapidly growing
neurological disease [2, 3]. Although symptomatic
treatments are available for the disabling motor and
some non-motor symptoms of the disease, these
treatments have not been shown to slow the progres-
sion of the underlying disease pathology. Thus, the
development of drugs that modify the course of the
disease is an important aim being pursued by indus-
try, academia and non-profit organizations. Recent
advances in PD research include the discovery and
development of promising targets [4, 5]. Yet drug
developers face many challenges in advancing new
treatments aimed at disease modification [6–8]. PD
is linked to toxic accumulation of aggregated forms
of the normal synaptic protein, -synuclein, in the
brain and peripheral nervous system. -synuclein
is the major component of Lewy bodies and Lewy
neurites, the hallmark pathology of PD. Rare point
mutations and the presence of extra copies of the
synuclein gene result in autosomal dominant PD
[9, 10]. Novel therapeutic development efforts are
underway targeting -synuclein [11] and the two
most common genetic causes of PD, glucocerebrosi-
dase (GBA) deficiency [12], and mutated forms of
leucine rich repeat kinase 2 (LRRK2) [4, 13]. Cellu-
lar processes considered to be valid targets for drug
development include the molecular processes leading
to -synuclein accumulation (synthesis, aggregation
and clearance), as well as mitochondrial dysfunction
and neuroinflammation [14]. Recent PD clinical tri-
als have focused on the following therapeutic targets:
calcium flux (Isradipine), brain levels of the antioxi-
dant, urate (Inosine), the c-Abl kinase (Nilotinib), and
insulin signalling via the GLP-1 receptor (Exenatide)
(reviewed by [5, 6]).
Regardless of molecular target, clinical studies
of agents intended to slow disease progression in
PD could benefit from application of biomarkers to
help enrich clinical trial populations with the most
appropriate patients for the study. This review high-
lights the formal qualification opinion issued by the
European Medicines Agency (EMA) for the use of
molecular neuroimaging of the dopamine transporter
(DAT) as an enrichment biomarker for use in PD clin-
ical trials. A manuscript focused on highlighting the
data analyses and regulatory aspects of this project
was recently published [62].
The need to identify clinical trial populations
using biomarkers and pathology
There is an emerging consensus among PD
researchers that, as with other neurodegenerative dis-
eases, disease modifying treatments are most likely
to be effective at an early stage of the disease,
when delaying progression and disability will be
most impactful. In fact, we have learned that motor
symptoms are only apparent after profound loss of
dopaminergic neurons in PD [15]. It can, however,
be challenging to diagnose PD, especially in early
stage disease when other neurological disorders can
present with similar signs and symptoms [16, 17].
Identifying the right participants to enroll in clinical
trials is critically important for early intervention and
is particularly challenging based on clinical criteria
alone [18]. One approach to identify the appropriate
participants is to use biomarkers, particularly in light
of increasing emphasis on precision medicine. Imag-
ing biomarkers have been employed in PD clinical
trials quite extensively primarily using dopaminergic
ligands. At present there is strong interest in devel-
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oping novel molecular imaging tracers, particularly
those such as synuclein radiotracers [19, 20] that will
enable confirmation of target engagement.
Deﬁning enrichment
The use of biomarkers to enrich the clinical trial
population, leading to a more homogenous treat-
ment cohort, is likely to address this challenge. There
are many examples to learn from; for example, in
therapeutic development in Alzheimer’s disease [23,
24]. A biomarker may be applied as an inclusion or
exclusion criterion to distinguish the targeted indi-
cation from another condition with a similar clinical
presentation but a different cause. For example, in
contemporary Alzheimer’s disease trials, an amy-
loid PET scan has been used to enrich the clinical
trial population by excluding subjects without fibril-
lar amyloid deposits in their brain [55]. This results in
a high screen failure rate but provided a more homo-
geneous population by excluding subjects whose
memory impairment is unlikely to be caused by amy-
loid pathology.
Regulatory authorities define “enrichment” as “the
prospective use of any patient characteristic to select a
study population in which detection of a drug effect (if
one is in fact present) is more likely than it would be in
an unselected population” [21]. Health authorities in
the US and Europe have encouraged the use of enrich-
ment biomarkers in clinical trials to support drug
development [22, 23–25]. Biomarkers for enrichment
are aimed at identifying a population of trial partic-
ipants who are more likely to progress or respond
to treatment. An example is the use of low baseline
hippocampal volume as an enrichment biomarker to
identify predementia subjects more likely to progress
in a clinical trial for early Alzheimer’s disease [26].
Ensuring consensus and broad adoption:
biomarker qualiﬁcation
The selection of biomarkers for use in clinical
trials conventionally merits a confidential discus-
sion between the regulator and the study’s sponsor
[5]. Regulators also offer biomarker qualification, a
public and formal review process to accelerate the
adoption of drug development tools across targets
and sponsors [23, 27, 28]. Regulatory qualification
provides a mechanism by which the regulators define
and endorse a biomarker for use in a clearly defined
way to support drug development. The development
of a strategic pathway for biomarker qualification
provides a uniform, consistent method for advancing
specific biomarkers for specific contexts. The explicit
methods of validation vary depending on the process
mapped out, yet regulatory guidance on qualification
affords clarity and transparency (21st Century Cures).
The “context of use” refers to the specific applica-
tion of the biomarker in drug development. Once
the regulators have qualified a particular biomarker
for a specified context of use, this biomarker gener-
ally does not require further regulatory review and
approval for use by sponsors in drug development
[28, 29].
Dopamine transporter imaging as an enrichment
biomarker
For therapeutic trials in patients with PD, drug
developers have an urgent need for effective biomark-
ers to enrich study patients and assess target
engagement, disease prognosis, and clinical response
[7–30]. There is not yet a reliable biofluid or imaging
biomarker of -synuclein to enrich PD clinical trial
populations [19, 20, 30, 57]. However, neuroimaging
biomarkers, particularly ones probing the dopamin-
ergic system in the brain, have been employed in PD
clinical trials for many years [31, 32]. The dopamine
transporter (DAT), a transporter protein that is located
on the presynaptic terminal of dopaminergic neurons,
can be imaged with specific molecular radiotracers
[33]. Reductions of DAT radiotracer binding (DAT
deficit) correlate with the disease duration from early
stages of the disease [34], matching pathological find-
ings from DAT immunohistochemistry [35]. Recent
studies demonstrate DAT deficit may be augmented
in synuclein mutation PD subjects [36].
The application of DAT in clinical trials can be
used to detect the absence of DAT-deficiency, termed
‘scans without evidence of dopaminergic deficit’
(SWEDD) [37]. Subjects defined as ‘SWEDD’ had
been identified at the end of specific clinical trials
when unblinding the imaging results even though
such subjects met clinically defined inclusion criteria
for PD at the study recruitment phase. The Parkinson
Progression Marker Initiative (PPMI) observational
study elected to identify a specific cohort of SWEDD
subjects at study onset and follow these subjects
longitudinally [38]. Although the pathological basis
for Parkinson-like symptoms in subjects identified
as SWEDD remains uncertain and no correlative
post-mortem data is yet available, data from mul-
tiple sources has indicated that motor deterioration
in SWEDD subjects is much slower than in sub-
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jects whose scans show evidence of dopamine nerve
terminal loss [39–44]. Data to date when looked
at collectively demonstrate that for cohorts enrolled
within one year of diagnosis approximately 10 to 15%
of subjects enrolled in PD clinical studies may lack
imaging evidence of dopamine deficiency at baseline
and that their disease progression will be significantly
slower than those who do.
Figure 2 illustrates that the proportion of SWEDD
subjects is greater in study populations closer to the
date of diagnosis. As clinical trial sponsors aim to
treat PD populations at earlier stages of the disease,
the value of enrichment with DAT imaging therefore
increases.
The radioligand (123I) -CIT, developed as a
selective tracer of the dopamine transporter, was
shown to be useful in the evaluation of PD and has
been used in several PD clinical research studies
and trials. Fluoroalkyl analogues were subsequently
introduced, which required shorter tracer uptake
times and which were somewhat more selective [45].
One of these DAT imaging agents (the single photon
emission tomography, SPECT, radiotracer Ioflupane
or 123I FP-CIT) was developed further and subse-
quently, approved as a medical product by both FDA
(DaTscan™) and EMA (DaTSCAN). It is available
widely throughout the world. At present, this DAT
imaging agent is approved for clinical use to assist
in the evaluation of patients with suspected parkin-
sonian syndromes to distingusih PD from essential
tremor [46].
The Critical Path for Parkinson’s (CPP) is a global
public-private partnership to accelerate drug devel-
opment in PD [47]. The Critical Path Institute in the
United States and Parkinson’s UK jointly sponsor
this collaboration. CPP is comprised of pharmaceu-
tical companies, academic researchers, government
agencies and advocacy research organizations col-
laborating to share data and development drug
development tools for regulatory acceptance.
CPP has proposed the use of DAT imaging as a
biomarker during the screening phase of clinical trials
of novel PD therapies, to enrich the selected popula-
tion, by excluding SWEDD subjects and thus provide
a more homogeneous study population. Conducting a
PD clinical study in such an enriched patient popula-
tion, can optimize trial sample size, thereby reducing
trial costs. Furthermore, such enrichment will direct
the treatment to the intended patients for whom the
evaluation of benefit and safety of the intervention
is intended, without unnecessarily exposing others to
therapeutic candidates.
In 2015 and 2016 respectively, the US FDA and
the EMA issued letters of support for use of DAT
imaging as a drug development tool as an enrich-
ment biomarker in early PD clinical trials [48, 49].
The letters of support originated from the Critical
Path Institute consortia, coalition Against Major Dis-
eases (CAMD) and CPP. The purpose of these formal
public letters issued is to communicate to the exter-
nal community the growing evidence for the use of
the biomarker and encourage sponsors to collect and
share relevant data supporting the biomarker use in
ongoing and prospective clinical trials.
Qualiﬁcation of DAT imaging as an enrichment
biomarker in early PD trials
The full qualification document including details
of the data analyses and imaging methodology rec-
ommendations can be found on the EMA website
[50]. The analyses that supported the qualification
opinion has been published [50, 62] and was accepted
for publication prior to the final regulatory qual-
ification. The qualification document contains the
operational details required to employ DAT SPECT
imaging in a clinical trial of patients with early motor
PD. The methodology outlining the foreseen use is
based on visual reads and fully aligns with recom-
mendations for use of DAT imaging in US [33] and
EU [51]. Figure 1 illustrates how this enrichment
biomarker is recommended for clinical trials based
on the proposed context of use.
Biomarker qualification requires a clear definition
of the application, stage of drug development and
the population studied. The context-of-use of the PD
imaging biomarker qualified by the EMA is outlined
below:
CONTEXT-OF-USE (COU) STATEMENT
General Area
Enrichment biomarker for clinical trials in early
motor Parkinson’s disease.
Target population for use
Patients with early motor PD, defined by the UK
Brain Bank Criteria as outlined below:
Having at least two of the following: resting
tremor, bradykinesia, rigidity (must have either rest-
ing tremor or bradykinesia); OR either asymmetric
resting tremor or asymmetric bradykinesia. Based on
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Fig. 1. Proposed flow chart to apply DAT imaging as an enrichment biomarker in clinical trials targeting subjects with motor signs of early
PD. Each of the four inclusion criteria / steps must be met for subjects to be successfully enrolled into the PD clinical trial. The clinical
criteria must be met before subjects undergo DAT SPECT imaging (final step).
above criteria, combinations could include: resting
tremor/bradykinesia, bradykinesia/rigidity, and rest-
ing tremor/rigidity.
• Symptom(s) or signs may include bradykinesia,
a 4–6 Hz resting tremor, muscle rigidity, or pos-
tural instability not caused by primary visual,
vestibular, cerebellar or proprioceptive dysfunc-
tion.
• Hoehn and Yahr Stage I or II at baseline.
Although postural instability is a common fea-
ture in PD, based on the inclusion criterion of
Hoehn and Yahr Stage I or II, postural instability
would not be expected in the target population.
Stage of drug development for use
All clinical stages of early PD drug development,
including proof of concept, dose-ranging through to
confirmatory clinical trials. This is not intended for
candidate therapies for more advanced stages of PD
such as drugs to treat levodopa induced dyskinesias.
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Fig. 2. The proportion of subjects with absence of DAT deficit in clinical trials increases with earlier stages of PD. A number of PD clinical
studies have identified subjects defined as SWEDD by employing DAT imaging at baseline and follow up. The proportion of subjects
defined as SWEDD decreases with the time since diagnosis for those in specific PD clinical studies targeting early stages of the disease. The
proportion of SWEDD subjects is lower in studies enrolling subjects with longer duration of disease. As sponsors enroll PD subjects earlier
in the disease (i.e., sooner after diagnosis), the value (benefit) of DAT imaging for enrichment increases. References for PD clinical studies:
[38, 39, 41, 59–61]. ELLDOPA: Levodopa; PRECEPT: Mixed Lineage Kinase Inhibitor CEP 1347; REAL-PD: Ropinirole; CALM-PD:
Pramipexole; GPI1485: Immunophilin; PPMI: Parkinson’s Progression Markers Initiative.
The predictive value of DAT imaging in a
realistic clinical trial setting
To support the EMA biomarker qualification, CPP
collected, standardized, and integrated data from two
clinical studies that employed DAT imaging namely,
PPMI [38] and PRECEPT [40, 52]. These studies had
similar clinical inclusion criteria and target popula-
tions at baseline, with equivalent visual reads based
on different DAT tracers. Two different versions of
the clinical score were used to track disease progres-
sion (MDS-UPDRS part III in PPMI versus UPDRS
part III in PRECEPT); these versions were homoge-
nized to the MDS-UPDRS part III for analyses of the
integrated data.
PRECEPT and PPMI represent uniquely rich
cohorts of well characterized subjects with early stage
PD where subject-level data was available to CPP for
analyses to support regulatory science goals. Both
studies include similar patient populations from mul-
ticenter global sites with application of DAT imaging
at baseline and long term clinical follow up. The
use of both observational and randomized clinical
trial (RCT) populations aided in the confidence of
predictability of the results to prospective trial popu-
lations that align with the proposed context-of-use.
Additional considerations worth noting are that
SWEDD subjects in PPMI learned their imaging
results after the baseline scans were interpreted.
Subjects were offered the opportunity to remain
enrolled in PPMI to advance the understanding of
PD and many opted to continue. In PRECEPT, all
subjects and clinicians remained blinded throughout
the duration of the clinical trial. SWEDD status was
not defined in PRECEPT until study completion.
The analysis of the integrated patient-level data
from both studies took careful account of the hetero-
geneity in specific variables. This integrated analysis
confirmed that, as a subpopulation, subjects who
had no evidence of DAT deficit (SWEDD subjects)
progressed more slowly than the subpopulation of
those classified with DAT deficiency. The change
from baseline of MDS-UPDRS part III at 24 months
was 4.28 points (90% CI: 3.45, 5.08) for those with
DAT deficit, and 1.12 points (90% CI: –0.98, 3.1) for
SWEDD subjects [53].
Patient-level longitudinal data of 672 early stage
PD subjects in the PPMI observational study and the
PRECEPT clinical trial were utilized in a linear mixed
effects model analysis. The rate of worsening in the
motor scores between subjects with and without DAT
deficit was different both statistically and clinically.
Since the application of the biomarker is intended
for clinical trial enrichment based on predictions of
continuous disease progression, examination of diag-
nostic sensitivity, specificity and predictive values
was not required for the analyses as this would lack
applicability in this context. Clinical trial simulations
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were carried out in order to understand the impact of
enrichment on sample sizes. For illustration, a trial
simulation analysis was based on the PPMI and PRE-
CEPT data and simulated a 24-month clinical trial
with or without enrichment with the DAT imaging
biomarker for subjects recruited soon after diagno-
sis. This analysis showed that using the DAT imaging
to include only subjects with confirmed dopamine
deficit resulted in a potential gain in statistical power
equivalent to a 24% reduction in sample size and
reduced the heterogeneity of the study population.
DAT imaging would thereby decrease the exposure
of non-PD patients to the therapeutic intervention
and increase the chance of successfully establish-
ing whether an experimental medicine is effective,
regardless of the drug’s specific mechanism of action.
Because the enrichment biomarker excludes sub-
jects that show minimal to no decline in disease
progression, this gain in statistical power is not spe-
cific to a therapeutic target but is generally applicable
to clinical trials in early motor PD soon after diagno-
sis. It is important to note that the qualification is for
the biomarker itself rather than a specific radiotracer
or commercial product.
Limitations of the biomarker
The limitations to the use of this imaging
biomarker include: 1) Any condition in which there is
loss of dopaminergic nerve terminals in the striatum,
such as progressive supranuclear palsy and multiple
system atrophy, will show reduced signal using DAT
imaging [32]. CPP is not proposing DAT imaging
for use as a diagnostic biomarker to differentiate the
various forms of degenerative Parkinsonism. 2) DAT
imaging in the present context is not to be applied
as a biomarker of target engagement in PD trials.
DAT is not specific to-synuclein and decreased DAT
levels cannot be equated with the presence of synu-
clein pathology in the brain. 3) The operational use of
the biomarker should be managed centrally in accor-
dance with the FDA guidance on imaging endpoints
for clinical trials [54], including the use of trained
central readers and 4) the diagnostic criteria that are
included in the qualification will need to be refined
to align with new criteria recognizing multiple stages
of early disease [55].
CONCLUSIONS
The EMA qualification opinion of DAT imaging
for PD clinical trials represents the first biomarker
qualified for use for PD clinical trials as a drug
development tool and is aimed to encourage the
advancement of therapies targeting early stages of the
disease. The current target population is early motor
PD, from 1 to 2 years of diagnosis. Given emerging
data demonstrating that accurate identification of PD
pathology poses significant challenges, particularly at
early stages [16] new biomarkers are urgently needed
for identifying the right subjects to recruit into clinical
trials. Imaging of synucleinopathies will be a step for-
ward for the field [19, 33] as well as the discovery and
validation of novel biomarkers for use in clinical tri-
als [56]. Continued work is needed to refine this tool
as an enrichment marker in future trials of patients in
the prodromal and even premotor stages of PD [57].
In addition, the use of longitudinal data from PPMI,
combined with interventional data from PRECEPT,
a legacy clinical trial conducted nearly 15 years ago,
demonstrates that data sharing from past and ongo-
ing PD clinical studies can optimize the opportunity
of success of future PD clinical trials. The overall
strategy aligns with recommendations for the future
vision of PD aimed at biomarker driven phenotypes
as the key strategy to enabling precision medicine
[58].
ACKNOWLEDGMENTS
The Critical Path Institute’s Critical Path for
Parkinson’s (CPP) Consortium is funded by Parkin-
son’s UK and the following industry members:
Abbvie, Biogen, Eli Lilly, GE Healthcare, Lundbeck,
Merck Sharp and Dohme, Pfizer, Roche, Denali,
Sanofi, GSK, Takeda and UCB. We also acknowledge
additional CPP member organizations, including
Parkinson’s Disease Foundation, Michael J. Fox
Foundation, Davis Phinney Foundation, The Cure
Parkinson’s Trust, University of Oxford, University
of Cambridge, Newcastle University, University of
Glasgow, Radboud University, NINDS, FDA, and
EMA.
The Critical Path Institute is supported in part by
grant number 5U18FD005320 from the Food and
Drug Administration. CPP acknowledges the strong
support of FDA liaison’s Dr. Gerald Podskalny and
Dr. Billy Dunn, Division of Neurology Products.
CPP recognizes Teva for contributing the PRE-
CEPT patient-level data, the PRECEPT study
investigators for their role in leading the study; Insti-
tute of Neurodegenerative Disorders for their efforts
in analysing the imaging results from both PRE-
560 D. Stephenson et al. / Regulatory Qualiﬁcation of Parkinson’s Imaging Biomarker
CEPT and PPMI; and the Michael J. Fox Foundation
for funding of PPMI. Data were obtained from the
Parkinson’s Progression Markers Initiative (PPMI)
database (http://www.ppmi-info.org/data). PPMI – a
public-private partnership – is funded by the Michael
J. Fox Foundation for Parkinson’s Research and
funding partners, including AbbVie, Avid, Biogen,
Bristol-Myers Squibb, Convance, GE Healthcare,
Genentech, GSK, Lilly, Lundbeck, Merck, Meso
Scale Discovery, Pfizer, Piramal, Roche, Sanofi
Genzyme, Servier, TEVA, UCB, and Golub Capi-
tal. For up-to-date information on the study, visit
http://www.ppmi-info.org.
The views expressed in this publication by the
authors from the European Medicines Agency are
the personal views of the authors and may not be
understood nor quoted as being made on behalf of or
reflecting the position of EMA or one of its com-
mittees or working parties or any of the national
agencies.
CPP recognizes contributions of the individual
members of the CPP imaging biomarker team and
the CPP modelling and simulation team. CPP rec-
ognizes the consortium’s scientific advisors: Karl
Kieburtz, Charles Venuto, E. Ray Dorsey, Bastiaan
R. Bloem. The CPP consortium recognizes Dr. Ira
Shoulson for his leadership as principal investigator
of the PRECEPT study in addition to the Parkin-
son’s Study Group. The following individuals are
acknowledged for their contributions to the project:
Patricia Cole, Igor Grachev, Grace Crotty, Volker
Kern, Steve Arneric, Mark Frasier, Alyssa Reimer
and Jamie Eberling.
Funding sources
Parkinson’s UK, Abbvie, Biogen, Eli Lilly, GE
Healthcare, GSK, Lundbeck, Merck Sharp and
Dohme, Pfizer, Denali, Sanofi, Takeda and UCB.
CONFLICTS OF INTEREST
Authors who are employed at pharmaceutical or
diagnostic companies have respective conflicts of
interest based on their affiliations.
MT, SV, DS, KR, DC, AR, JG, DD, SI have no
conflicts of interest
JS: Consultant (Biogen, Roche, LikeMinds, Life
Molecular Imaging); Equity (Invicro)
DG: received grant funding from the Neu-
rosciences Foundation, Michael’s Movers, and
Parkinson’s UK, and honoraria from Bial Pharma-
ceuticals and GE Healthcare.
GS: received grant funding from NIH, Michael J
Fox Foundation and honoraria from Biogen
KM: received funding from the The Michael J.
Fox Foundation, the US Department of Defense and
is employed by Invicro and has received consul-
tant fees from Pfizer, GE Healthcare, Lilly, BMS,
Piramal, Biogen, Prothena, Roche, Neuropore,US
Worldmeds, Neurophage, UCB, Oxford Biomedica,
Lysosomal Therapetic, Inc, Neuroderm, Denali and
the Michael J. Fox Foundation.
REFERENCES
[1] Reeve A, Simcox E, Turnbull D (2014) Ageing and Parkin-
son’s disease: Why is advancing age the biggest risk factor?
Ageing Res Rev 14, 19-30.
[2] Dorsey ER, Sherer T, Okun MS, Bloem BR (2018) The
emerging evidence of the Parkinson pandemic. J Parkinsons
Dis 8, S3-S8.
[3] Rocca WA (2018) The burden of Parkinson’s disease: A
worldwide perspective. Lancet Neurol 17, 928-929.
[4] Sardi SP, Cedarbaum JM, Brundin P (2018) Targeted ther-
apies for Parkinson’s disease: From genetics to the clinic:
Targeted Therapies for PD. Mov Disord 33, 684-696.
[5] Kieburtz K, Katz R, Olanow C. Warren (2017) New drugs
for Parkinson’s disease: The regulatory and clinical devel-
opment pathways in the United States. Mov Disord 33,
920-927.
[6] Lang AE, Espay AJ (2018) Disease modification in Parkin-
son’s disease: Current approaches, challenges, and future
considerations: Disease modification in PD. MovDisord 33,
660-677.
[7] Cedarbaum JM (2018) Parkinson’s disease and “proof of
concept” clinical trials. Mov Disord 33, 697-700.
[8] Stoessl AJ (2017) Challenges and unfulfilled promises in
Parkinson’s disease. Lancet Neurol 16, 866-867.
[9] Konno T, Ross OA, Puschmann A, Dickson DW, Wszolek
ZK (2016) Autosomal dominant Parkinson’s disease caused
by SNCA duplications. Parkinsonism Relat Disord 22, S1-
S6.
[10] Olgiati S, Thomas A, Quadri M, Breedveld GJ, Graafland
J, Eussen H, Douben H, de Klein A, Onofrj M, Bonifati V
(2015) Early-onset parkinsonism caused by alpha-synuclein
gene triplication: Clinical and genetic findings in a novel
family. Parkinsonism Relat Disord 21, 981-986.
[11] Kingwell K (2017) Zeroing in on neurodegenerative -
synuclein. Nat Rev Drug Discov 16, 371-373.
[12] Siebert M, Sidransky E, Westbroek W (2014) Glucocere-
brosidase is shaking up the synucleinopathies. Brain 137,
1304-1322.
[13] Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lin-
coln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl
AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus
F, Mu¨ller-Myhsok B, Dickson DW, Meitinger T, Strom
TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2
cause autosomal-dominant parkinsonism with pleomorphic
pathology. Neuron 44, 601-607.
D. Stephenson et al. / Regulatory Qualiﬁcation of Parkinson’s Imaging Biomarker 561
[14] Valera E, Masliah E (2016) Therapeutic approaches in
Parkinson’s disease and related disorders. JNeurochem 139,
346-352.
[15] Hornykiewicz O (1998) Biochemical aspects of Parkinson’s
disease. Neurology 51, S2-S9.
[16] Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN,
Driver-Dunckley E, Sabbagh MN, Sue LI, Jacobson SA,
Belden CM, Dugger BN (2014) Low clinical diagnostic
accuracy of early vs advanced Parkinson disease clinico-
pathologic study. Neurology 83, 406-412.
[17] Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A,
Logroscino G (2016) Accuracy of clinical diagnosis of
Parkinson disease A systematic review and meta-analysis.
Neurology 86, 566-576.
[18] Beach TG, Adler CH (2018) Importance of low diagnos-
tic accuracy for early Parkinson’s disease: Low diagnostic
accuracy for early PD. Mov Disord 33, 1551-1554.
[19] Eberling JL, Dave KD, Frasier MA (2013) -synuclein
imaging: A critical need for Parkinson’s disease research. J
Parkinsons Dis 3, 565-567.
[20] Shah M, Seibyl J, Cartier A, Bhatt R, Catafau AM
(2014) Molecular imaging insights into neurodegeneration:
Focus on alpha-synuclein radiotracers. J Nucl Med 55,
1397-1400.
[21] FDA (2012) Guidance for Industry - Enrichment Strategies
for Clinical Trials to Support Approval of Human Drugs
and Biological Products. December 2012. https://www.
fda.gov/downloads/Drugs/GuidanceComplianceRegulatory
Information/Guidances/UCM332181.pdf. Accessed Jan-
uary 17, 2019. FDA (2019) Enrichment Strategies for
Clinical Trials to Support Determination of Effectiveness
of Human Drugs and Biological Products Guidance for
Industry. March 2019.
[22] FDA (2018) Early Alzheimer’s Disease: Developing Drugs
for Treatment; Guidance for Industry, Food and Drug
Administration, Silver Spring, MD. Food and Drug Admin-
istration; 2018. https://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/
UCM596728.pdf.
[23] Isaac M, Gispen-de Wied C (2015) CNS biomarkers:
Potential from a regulatory perspective. Eur Neuropsy-
chopharmacol 25, 1003-1009.
[24] Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn
B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F,
Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C,
Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM,
Sperling R, Elliott C, Masliah E, Ryan L, Silverberg N
(2018) NIA-AA Research Framework: Toward a biological
definition of Alzheimer’s disease. Alzheimers Dement 14,
535-562.
[25] Haas M, Mantua V, Haberkamp M, Pani L, Isaac M,
Butlen-Ducuing F, Vamvakas S, Broich K (2015) The
European Medicines Agency’s strategies to meet the chal-
lenges of Alzheimer disease. Nat Rev Drug Discov 14,
221-222.
[26] Hill DLG, Schwarz AJ, Isaac M, Pani L, Vamvakas S,
Hemmings R, Carrillo MC, Yu P, Sun J, Beckett L, Boc-
cardi M, Brewer J, Brumfield M, Cantillon M, Cole PE,
Fox N, Frisoni GB, Jack C, Kelleher T, Luo F, Novak G,
Maguire P, Meibach R, Patterson P, Bain L, Sampaio C,
Raunig D, Soares H, Suhy J, Wang H, Wolz R, Stephen-
son D (2014) Coalition Against Major Diseases/European
Medicines Agency biomarker qualification of hippocam-
pal volume for enrichment of clinical trials in predementia
stages of Alzheimer’s disease. Alzheimers Dement 10, 421-
429.e3.
[27] Leptak C, Menetski JP, Wagner JA, Aubrecht J, Brady L,
Brumfield M, Chin WW, Hoffmann S, Kelloff G, Lavez-
zari G (2017) What evidence do we need for biomarker
qualification? Sci Transl Med 9, eaal4599.
[28] Manolis E, Koch A, Deforce D, Vamvakas S (2015) The
European Medicines Agency experience with biomarker
qualification. In Clinical Proteomics: Methods and Proto-
cols, Vlahou A, Makridakis M, eds. Springer New York,
New York, NY, pp. 255-272.
[29] Amur S, LaVange L, Zineh I, Buckman-Garner S, Wood-
cock J (2015) Biomarker qualification: Toward a multiple
stakeholder framework for biomarker development, regula-
tory acceptance, and utilization. Clin Pharmacol Ther 98,
34-46.
[30] Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eber-
ling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J,
Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner
DM (2019) A proposed roadmap for Parkinson’s disease
proof of concept clinical trials investigating compounds tar-
geting alpha-synuclein. J Parkinsons Dis 9, 31-61.
[31] Brooks DJ, Pavese N (2011) Imaging biomarkers in Parkin-
son’s disease. Prog Neurobiol 95, 614-628.
[32] Brooks DJ (2016) Molecular imaging of dopamine trans-
porters. Ageing Res Rev 30, 114-121.
[33] Djang DSW, Janssen MJR, Bohnen N, Booij J, Henderson
TA, Herholz K, Minoshima S, Rowe CC, Sabri O, Seibyl J,
Van Berckel BNM, Wanner M (2012) SNM practice guide-
line for dopamine transporter imaging with 123I-Ioflupane
SPECT 1.0. J Nucl Med 53, 154-163.
[34] Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K,
van Royen E, Speelman JD, Horstink MH, Sips HJ, Dier-
ckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley
DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel
WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz
J, Ries V (2000) Accurate differentiation of parkinsonism
and essential tremor using visual assessment of [123I]-FP-
CIT SPECT imaging: The [123I]-FP-CIT study group. Mov
Disord 15, 503-510.
[35] Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG,
Adler CH, Halliday GM, Bartus RT (2013) Disease duration
and the integrity of the nigrostriatal system in Parkinson’s
disease. Brain 136, 2419-2431.
[36] Koros C, Simitsi A, Prentakis A, Beratis I, Papadimitriou D,
Kontaxopoulou D, Fragkiadaki S, Papagiannakis N, Seibyl
J, Marek K, Papageorgiou SG, Trapali XG, Stamelou M,
Stefanis L (2018) 123I-FP-CIT SPECT [(123) I-2-carbo-
methoxy-3-(4-iodophenyl)-N-(3-fluoropropyl)nortropane
single photon emission computed tomography] Imaging in
a p.A53T -synuclein Parkinson’s disease cohort versus
Parkinson’s disease: 123I-FP-CIT imaging in a P.A53T PD
cohort. Mov Disord 33, 1734-1739.
[37] Marek K, Jennings D, Seibyl J (2003) Single photon
emission tomography and dopmaim transporter imaging in
Parkinson’s disease. Adv Neurol 91, 183-191.
[38] Marek K, Jennings D, Lasch S, Siderowf A, Tanner C,
Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S,
Poewe W, Mollenhauer B, Klinik P-E, Sherer T, Frasier
M, Meunier C, Rudolph A, Casaceli C, Seibyl J, Mendick
S, Schuff N, Zhang Y, Toga A, Crawford K, Ansbach A,
De Blasio P, Piovella M, Trojanowski J, Shaw L, Singleton
A, Hawkins K, Eberling J, Brooks D, Russell D, Leary L,
Factor S, Sommerfeld B, Hogarth P, Pighetti E, Williams
562 D. Stephenson et al. / Regulatory Qualiﬁcation of Parkinson’s Imaging Biomarker
K, Standaert D, Guthrie S, Hauser R, Delgado H, Jankovic
J, Hunter C, Stern M, Tran B, Leverenz J, Baca M, Frank
S, Thomas C-A, Richard I, Deeley C, Rees L, Sprenger
F, Lang E, Shill H, Obradov S, Fernandez H, Winters A,
Berg D, Gauss K, Galasko D, Fontaine D, Mari Z, Ger-
stenhaber M, Brooks D, Malloy S, Barone P, Longo K,
Comery T, Ravina B, Grachev I, Gallagher K, Collins M,
Widnell KL, Ostrowizki S, Fontoura P, Ho T, Luthman J,
Brug M van der, Reith AD, Taylor P (2011) The Parkinson
Progression Marker Initiative (PPMI). Prog Neurobiol 95,
629-635.
[39] Parkinson Study Group (2007) Mixed lineage kinase
inhibitor CEP-1347 fails to delay disability in early Parkin-
son disease. Neurology 69, 1480.
[40] Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang
AE, Hyson C, Jennings D (2014) Longitudinal follow-up
of SWEDD subjects in the PRECEPT Study. Neurology 82,
1791-1797.
[41] Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S,
Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P,
Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study
Group (2003) Slower progression of Parkinson’s disease
with ropinirole versus levodopa: The REAL-PET study. Ann
Neurol 54, 93-101.
[42] Erro R, Schneider SA, Stamelou M, Quinn NP, Bhatia KP
(2016) What do patients with scans without evidence of
dopaminergic deficit (SWEDD) have? New evidence and
continuing controversies. J Neurol Neurosurg Psychiatry
87, 319-323.
[43] Seibyl J, Marek K, Zubal IG (2010) The role of the core
imaging laboratory in multicenter trials. Semin Nucl Med
40, 338-346.
[44] Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio
A, Beal F, Beck J, Flagg E, Galpern WR, Harman J,
Lang AE, Schwarzschild M, Tanner C, Shoulson I (2012)
Dopamine transporter imaging is associated with long-term
outcomes in Parkinson’s disease. Mov Disord 27, 1392-
1397.
[45] Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-
Ponce Y, Zoghbi SS, Baldwin RM, Laruelle M, Chamey
DS, Hoffer PB, Neumeyer JL, Innis RB (1996) SPECT
imaging of dopamine transporters in human brain with
iodine-123-fluoroalkyl analogs of n-CIT. J Nucl Med 37,
1129-1134.
[46] Bajaj N, Hauser RA, Grachev ID (2013) Clinical util-
ity of dopamine transporter single photon emission CT
(DaT-SPECT) with (123I) ioflupane in diagnosis of parkin-
sonian syndromes. J Neurol Neurosurg Psychiatry 84,
1288-1295.
[47] Stephenson D, Hu MT, Romero K, Breen K, Burn D, Ben-
Shlomo Y, Bhattaram A, Isaac M, Venuto C, Kubota K, Little
MA, Friend S, Lovestone S, Morris HR, Grosset D, Suther-
land M, Gallacher J, Williams-Gray C, Bain LJ, Avile´s E,
Marek K, Toga AW, Stark Y, Forrest Gordon M, Ford S
(2015) Precompetitive data sharing as a catalyst to address
unmet needs in Parkinson’s disease. J Parkinsons Dis 5,
581-594.
[48] EMA (2016) Letter of support for molecular imaging
of the dopamine transporter biomarker as an enrichment
biomarker for clinical trials for early Parkinson’s disease.
September 2016. http://www.ema.europa.eu/docs/en GB/
document library/Other/2016/10/WC500213914.pdf;
[49] FDA (2015) Biomarker Letter of Support. Parkin-
son’s Imaging Biomarker. https://www.fda.gov/downloads/
Drugs/DevelopmentApprovalProcess/DrugDevelopmentTo
olsQualificationProgram/BiomarkerQualificationProgram/
UCM605357.pdf.
[50] EMA, Committee for Medicinal Products for Human Use
(CHMP) (2018) Qualification opinion on dopamine trans-
porter imaging as an enrichment biomarker for Parkinson’s
disease clinical trials in patients with early Parkinsonian
symptoms. May 2018. https://www.ema.europa.eu/docum
ents/regulatory-procedural-guideline/qualification-opinion
-dopamine-transporter-imaging-enrichment-biomarker-par
kinsons-disease-clinical en.pdf.
[51] Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T,
Kapucu ¨OL, Na˚gren K, Nobili F, Walker Z, Van Laere K
(2010) EANM procedure guidelines for brain neurotrans-
mission SPECT using 123I-labelled dopamine transporter
ligands, version 2. Eur J Nucl Med Mol Imaging 37, 443-
450.
[52] Parkinson Study Group (2002) Dopamine transporter brain
imaging to assess the effects of pramipexole vs lev-
odopa on parkinson disease progression. JAMA 287, 1653-
1661.
[53] Conrado DJ, Nicholas T, Tsai K, Macha S, Sinha V, Stone
J, Corrigan B, Bani M, Muglia P, Watson IA, Kern VD,
Sheveleva E, Marek K, Stephenson DT, Romero K, on
behalf of the Critical Path for Parkinson’s (CPP) Parkin-
son’s Disease Modeling and Simulation Working Group
(2017) Dopamine transporter neuroimaging as an enrich-
ment biomarker in early Parkinson’s disease clinical trials:
A disease progression modeling analysis: Dopamine trans-
porter imaging enrichment biomarker. Clin Transl Sci 11,
63-70.
[54] FDA, U.S. Department of Health and Human Services.
Clinical Trial Imaging Endpoint Process Standards Guid-
ance for Industry https://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/
UCM268555.pdf.
[55] Postuma RB, Gagnon J-F, Pelletier A, Montplaisir JY
(2017) Insomnia and somnolence in idiopathic RBD: A
prospective cohort study. NPJ Parkinsons Dis 3, 9.
[56] Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V,
Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson
MR, Dawson TM, Dewey R, Foroud T, Frasier M, Ger-
man D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S,
Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A,
Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R,
Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I,
Walt D, West A, Zhang J (2018) Finding useful biomarkers
for Parkinson’s disease. Sci Transl Med 10, eaam6003.
[57] Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes
D, Marek K, for the PARS Investigators (2017) Conversion
to Parkinson disease in the PARS Hyposmic and Dopamine
Transporter-Deficit Prodromal Cohort. JAMA Neurol 74,
933.
[58] Espay AJ, Schwarzschild MA, Tanner CM, Fernandez
HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin
A, Brundin P, Kauffman MA, Erro R, Kieburtz K,
Woo D, Macklin EA, Standaert DG, Lang AE (2017)
Biomarker-driven phenotyping in Parkinson’s disease: A
translational missing link in disease-modifying clinical
trials: Molecular phenotyping For PD. Mov Disord 32,
319-324.
[59] NINDS NET-PD Investigators (2007) NINDS NET-PD
Investigators (2007) A randomized clinical trial of coen-
zyme Q10 and GPI-1485 in early PD. Neurology 68, 20-8.
D. Stephenson et al. / Regulatory Qualiﬁcation of Parkinson’s Imaging Biomarker 563
[60] Fahn S (1999) Parkinson disease, the effect of levodopa, and
the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol
56, 529-535.
[61] Parkinson Study Group (2000) A randomized controlled
trial comparing pramipexole with levodopa in early Parkin-
son’s disease: Design and methods of the CALM-PD Study.
Clin Neuropharmacol 23, 34-44.
[62] Romero K, Conrado D, Burton J, Nicholas T, Sinha V,
Macha S, Ahamadi M, Cedarbaum J, Seibyl J, Marek K,
Basseches P, Hill D, Somer E, Gallagher J, Dexter DT,
Roach A, Stephenson D; Critical Path for Parkinson’s (CPP)
Consortium; Parkinson’s Progression Markers Initiative
(PPMI) (2019) molecular neuroimaging of the dopamine
transporter (DAT) as a patient enrichment biomarker for
clinical trials for early Parkinson disease. Clin Transl Sci
12, 240-246.
